- Dosage: Artesunate 200mg, Amodiaquine 600mg
- Packaging: 6tablets/blister*10/box
- Shelf Life: 36months
Package:
Product Description
Artesunate 200mg + Amodiaquine 600mg Tablets: What the Published Guidance Says
Artemisinin-based combination therapy is the WHO-recommended backbone of falciparum malaria treatment.
This page collects the supply-relevant facts for Artesunate 200mg + Amodiaquine 600mg Tablets — specification, testing, packaging and the registration paperwork that travels with the batch.
- ACT is the treatment of choice in all trimesters For uncomplicated P. falciparum malaria, MSF medical guidelines state the treatment of choice in all trimesters is an artemisinin-based combination therapy taken for three days. Co-formulated and co-blistered regimens are both described, including artemether/lumefantrine 20/120 mg and 80/480 mg, artesunate/amodiaquine, artesunate/mefloquine and dihydroartemisinin/piperaquine. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
- The ACT combinations and their strengths are specified on the WHO Model List Section 6.5.3.1 of the 24th WHO Model List (2025) specifies the curative antimalarials, including artemether + lumefantrine tablet 20 mg + 120 mg and a dispersible tablet, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine as granules and tablets, dihydroartemisinin + piperaquine across four tablet strengths, and artesunate co-packaged with sulfadoxine + pyrimethamine. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
- One combination to handle with care MSF notes that the artesunate + sulfadoxine/pyrimethamine combination is contraindicated in HIV-infected women taking co-trimoxazole preventive therapy, and that artesunate/mefloquine should not be used where neurological signs developed during the acute phase. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
Each point above is reproduced because it has a practical consequence for Artesunate 200mg + Amodiaquine 600mg Tablets: the strength you can register, the pack you can release, or the wording permitted on the label. Your national prescribing information always takes precedence.
Ordering Parameters for Artesunate 200mg + Amodiaquine 600mg Tablets
| Product Name | Artesunate + Amodiaquine Tablets (Artesunate 200mg + Amodiaquine 600mg Combination Tablets) |
| Specification | Each tablet contains: Artesunate 200mg + Amodiaquine 600mg (as amodiaquine hydrochloride) |
| Dosage Form | Oral Film-Coated Tablet (for oral administration) |
| Active Ingredient | Artesunate + Amodiaquine (amodiaquine hydrochloride) |
| Pharmacological Class | Antimalarial / Artemisinin Combination Therapy (ACT) |
| Route of Administration | Oral administration (swallowed whole with water; take with food or milk to enhance absorption and reduce gastrointestinal effects). |
| Storage | Store below 25°C, in a dry place, protected from light and moisture. Keep blister pack sealed until use. Do not freeze. |
| Therapeutic group | Malaria & ACTs — Malaria & ACTs |
| Manufacturer | Sinophare Bio-technology Co., Ltd. (GMP, China) |
| Documentation supplied | COA, HPLC/GC data, stability data, dossier package |
The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Chloroquine Phosphate 500mg Tablets, Dihydroartemisinin 40mg + Piperaquine 320mg Tablets, Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg, Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg, Artesunate 400mg Mefloquine 500mg Tablets, Artemether Lumefantrine 80/480mg Tablets, Artesunate Suppositories 100mg, Artemether 80mg Injection.
Pharmacopoeial Standard, Release Testing & COA
Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.
Release testing for Artesunate 200mg + Amodiaquine 600mg Tablets follows the monograph you nominate — USP, EP, BP or CP. If the presentation is not covered by a monograph, the specification is frozen in writing with your quality team before the batch is manufactured.
Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.
The quality control package for the marketed pack covers:
- Testing for microbial limits and preservative efficacy (multi-dose presentations)
- Testing for heavy metals and elemental impurities
- Testing for packaging integrity and seal testing
- Testing for description and identification
- Testing for assay of the active substance
- Testing for related substances and impurities
COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.
Packing, Labelling Languages & Export Paperwork
- Pack size: Blister pack (PVC-Alu), typically 18 tablets per box (3 treatment courses of 6 tablets each). Non-standard pack sizes can be quoted against your artwork.
- Storage: Store below 25°C, in a dry place, protected from light and moisture. Keep blister pack sealed until use. Do not freeze..
- Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
- Labelling: we typeset the carton and leaflet in English, Arabic, French, Russian and Spanish and in any further language your market requires, carrying your own brand where the local rules allow.
- Export: commercial invoice, packing list, certificate of origin, GMP certificate, COA and the free-sale certificate issued by the country of manufacture whenever your customs or regulator asks for it.
Marketing Authorisation & Tender Support
The legal manufacturer named on every document for Artesunate 200mg + Amodiaquine 600mg Tablets is Sinophare Bio-technology Co., Ltd., DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. The same entity appears on the GMP certificate and on the dossier submitted to your regulator.
- Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
- CTD dossier modules 1–5 in editable and PDF form, with the finished-product and API sections cross-referenced.
- Site Master File and GMP certificate for the manufacturing workshops.
- Method validation, stability protocol and the shelf-life justification for the marketed pack.
- Answers to authority questions during assessment, handled by the regulatory contact who prepared the file.
Artesunate 200mg + Amodiaquine 600mg Tablets is presented here against ACT regimens named in the WHO Model List of Essential Medicines. Inclusion in an essential-medicines list does not authorise sale in any particular country — the marketing authorisation for that market is a separate step.
Artesunate 200mg + Amodiaquine 600mg Tablets: Common Procurement Questions
What pack size is available for Artesunate 200mg + Amodiaquine 600mg Tablets?
Standard commercial packaging for this line is Blister pack (PVC-Alu), typically 18 tablets per box (3 treatment courses of 6 tablets each). Alternative pack sizes are produced to your specification and are supported by the corresponding stability data.
What documentation comes with a shipment of Artesunate 200mg + Amodiaquine 600mg Tablets?
The documentation set for every shipment includes the certificate of analysis (description, identification, assay, related substances), stability data for the marketed pack, and the site GMP certificate. Shelf life: 36 months.
Does the batch documentation for Artesunate 200mg + Amodiaquine 600mg Tablets support a registration filing?
The documentation set for every shipment includes the certificate of analysis (description, identification, assay, related substances), stability data for the marketed pack, and the site GMP certificate. Shelf life: 36 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.
Can you support registration in my market?
We provide COA, HPLC and GC analytical data, stability data, DMF and dossier packages together with registration support documents. DML Number Jin20160068 covers our medicines production.
What is the difference between artesunate and artemether for injection?
Artesunate is the WHO drug of choice for severe malaria and may be given intravenously or intramuscularly at 2.4 mg/kg. Artemether is an alternative given intramuscularly at 3.2 mg/kg on admission then 1.6 mg/kg daily, and must never be given intravenously.
Products Commonly Ordered with Artesunate 200mg + Amodiaquine 600mg Tablets
- Chloroquine Phosphate 500mg Tablets — 500mg
- Dihydroartemisinin 40mg + Piperaquine 320mg Tablets — 40mg
- Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg — 175mg
- Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg — 175mg
- Artesunate 400mg Mefloquine 500mg Tablets — 400mg
- Artemether Lumefantrine 80/480mg Tablets — 80mg
Browse the full Malaria & ACTs range; all Tablets; the complete product catalogue.
Request a Quotation for Artesunate 200mg + Amodiaquine 600mg Tablets
Tell us the monograph, pack size and quantity required for Artesunate 200mg + Amodiaquine 600mg Tablets 200mg, together with the destination market, and the quotation will state lead time and the documents that ship with the batch. Samples for registration can be added to the same order.
Sources & Regulatory Notes
- MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
- WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.
